
PMC:7696151 / 90544-92439
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
2744 | 1112-1115 | Gene | denotes | DCX | Gene:1641 |
2745 | 1166-1169 | Gene | denotes | DCX | Gene:1641 |
2746 | 1312-1315 | Gene | denotes | DCX | Gene:1641 |
2747 | 1604-1607 | Gene | denotes | DCX | Gene:1641 |
2748 | 19-30 | Species | denotes | T. whipplei | Tax:2039 |
2749 | 116-127 | Species | denotes | T. whipplei | Tax:2039 |
2750 | 135-140 | Species | denotes | human | Tax:9606 |
2751 | 509-517 | Species | denotes | patients | Tax:9606 |
2752 | 668-679 | Species | denotes | T. whipplei | Tax:2039 |
2753 | 1040-1051 | Species | denotes | C. burnetii | Tax:777 |
2754 | 1123-1134 | Species | denotes | T. whipplei | Tax:2039 |
2755 | 1186-1197 | Species | denotes | T. whipplei | Tax:2039 |
2756 | 1341-1349 | Species | denotes | patients | Tax:9606 |
2757 | 710-743 | Chemical | denotes | trimethoprim and sulfamethoxazole | |
2758 | 835-847 | Chemical | denotes | trimethoprim | MESH:D014295 |
2759 | 892-908 | Chemical | denotes | sulfamethoxazole | MESH:D013420 |
2760 | 1116-1119 | Chemical | denotes | HCQ | MESH:D006886 |
2761 | 1331-1334 | Chemical | denotes | HCQ | MESH:D006886 |
2762 | 1583-1586 | Chemical | denotes | HCQ | MESH:D006886 |
2763 | 1694-1697 | Chemical | denotes | DXC | MESH:D004318 |
2764 | 1766-1777 | Chemical | denotes | ceftriaxone | MESH:D002443 |
2765 | 76-93 | Disease | denotes | Whipple’s disease | MESH:D008061 |
2766 | 265-274 | Disease | denotes | infection | MESH:D007239 |
2767 | 338-346 | Disease | denotes | diarrhea | MESH:D003967 |
2768 | 363-376 | Disease | denotes | malabsorption | MESH:D008286 |
2769 | 382-393 | Disease | denotes | weight loss | MESH:D015431 |
2770 | 413-426 | Disease | denotes | Joint disease | MESH:D007592 |
2771 | 555-572 | Disease | denotes | cardiac disorders | MESH:D006331 |
2772 | 612-629 | Disease | denotes | Whipple’s disease | MESH:D008061 |
2773 | 1052-1062 | Disease | denotes | infections | MESH:D007239 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T237 | 338-346 | Phenotype | denotes | diarrhea | http://purl.obolibrary.org/obo/HP_0002014 |
T238 | 363-376 | Phenotype | denotes | malabsorption | http://purl.obolibrary.org/obo/HP_0002024 |
T239 | 382-393 | Phenotype | denotes | weight loss | http://purl.obolibrary.org/obo/HP_0001824 |
T240 | 413-426 | Phenotype | denotes | Joint disease | http://purl.obolibrary.org/obo/HP_0001367 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T576 | 0-94 | Sentence | denotes | On the other hand, T. whipplei is a Gram-positive bacterium responsible for Whipple’s disease. |
T577 | 95-249 | Sentence | denotes | The natural niche of T. whipplei is the human intestine since, in the intestinal mucosa, the bacterium is taken by macrophages, where it replicates [147]. |
T578 | 250-412 | Sentence | denotes | This bacterial infection is primally characterized by digestive tract disorders such as diarrhea (75% of cases), malabsorption, and weight loss (80–90% of cases). |
T579 | 413-524 | Sentence | denotes | Joint disease may appear more than six years before the diagnosis and occur in more than 80% of patients [148]. |
T580 | 525-630 | Sentence | denotes | Furthermore, neurological and cardiac disorders can also be frequently associated with Whipple’s disease. |
T581 | 631-791 | Sentence | denotes | For years the standard treatment for T. whipplei has included a combination of trimethoprim and sulfamethoxazole; however, relapses were not uncommon [149,150]. |
T582 | 792-1001 | Sentence | denotes | Later, in vitro studies, demonstrated that trimethoprim was inactive on this bacterium [154], while sulfamethoxazole induced bacterial resistance, making the co-administration completely ineffective [154,156]. |
T583 | 1002-1165 | Sentence | denotes | Based on the good results of treating C. burnetii infections, it was decided to test in vitro the association DCX/HCQ on T. whipplei, obtaining good results [154]. |
T584 | 1166-1255 | Sentence | denotes | DCX/HCQ efficacy on T. whipplei diseases was demonstrated in a clinical trial dated 2014. |
T585 | 1256-1473 | Sentence | denotes | This study showed that the administration of 200 mg/day DCX and 600 mg/day HCQ to 13 patients results in better outcomes (0/13 failures) even after 1 year of treatment, compared to standard antibiotics regimens [155]. |
T586 | 1474-1723 | Sentence | denotes | To date, several case reports available in the literature supported a therapy consisting of a combination of HCQ (600 mg/day) and DCX (200 mg/day) for a lifetime or at least one year, followed by a maintenance dosage of DXC used alone [156,157,158]. |
T587 | 1724-1895 | Sentence | denotes | In some cases, prophylaxis of intravenous ceftriaxone (2g/day) for the first two weeks followed by HCQ/DXC for at least 12–18 months has been recommended [72,159,160,161]. |